| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
|
Mansfield, A.S.
|
|
|
27 |
11 |
p. 2111-2117
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
27 |
11 |
p. ii-iii
|
artikel
|
| 3 |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
|
Yang, J.C.-H.
|
|
|
27 |
11 |
p. 2103-2110
|
artikel
|
| 4 |
Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysis
|
Myung, S.-K.
|
|
|
27 |
11 |
p. 2139
|
artikel
|
| 5 |
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues
|
Bentivegna, E.
|
|
|
27 |
11 |
p. 1994-2004
|
artikel
|
| 6 |
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
|
Vrdoljak, E.
|
|
|
27 |
11 |
p. 2046-2052
|
artikel
|
| 7 |
Global trends and predictions in ovarian cancer mortality
|
Malvezzi, M.
|
|
|
27 |
11 |
p. 2017-2025
|
artikel
|
| 8 |
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study
|
Furlanetto, J.
|
|
|
27 |
11 |
p. 2053-2059
|
artikel
|
| 9 |
Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?
|
Roviello, G.
|
|
|
27 |
11 |
p. 2131-2133
|
artikel
|
| 10 |
No ‘cure’ within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989–2011
|
Woods, L.M.
|
|
|
27 |
11 |
p. 2025-2031
|
artikel
|
| 11 |
Ovarian cancer mortality trends: which factors are involved?
|
Weiderpass, E.
|
|
|
27 |
11 |
p. 1977-1978
|
artikel
|
| 12 |
Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial † † Study presented in part at ESMO 2014 Congress, Madrid, Spain, 26–30 September 2014.
|
Lonardi, S.
|
|
|
27 |
11 |
p. 2074-2081
|
artikel
|
| 13 |
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
|
Liu, J.F.
|
|
|
27 |
11 |
p. 2124-2130
|
artikel
|
| 14 |
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
|
Vuylsteke, P.
|
|
|
27 |
11 |
p. 2059-2066
|
artikel
|
| 15 |
Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial
|
Ceccarelli, G.
|
|
|
27 |
11 |
p. 2137-2138
|
artikel
|
| 16 |
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
|
Aapro, M.
|
|
|
27 |
11 |
p. 2039-2045
|
artikel
|
| 17 |
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
|
Olaussen, K.A.
|
|
|
27 |
11 |
p. 2004-2016
|
artikel
|
| 18 |
Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer
|
Kinoshita, T.
|
|
|
27 |
11 |
p. 2117-2123
|
artikel
|
| 19 |
Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.
|
Kim, S.J.
|
|
|
27 |
11 |
p. 2133-2134
|
artikel
|
| 20 |
Reply to the letter to the editor ‘Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysis, by S.-K. Myung’
|
Bagnardi, V.
|
|
|
27 |
11 |
p. 2139-2140
|
artikel
|
| 21 |
reply to the letter to the editor ‘Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial’ by Ceccarelli et al.
|
Lacouture, M.E.
|
|
|
27 |
11 |
p. 2138-2139
|
artikel
|
| 22 |
Reply to the letter to the editor ‘Utilisation of the ESMO-MCBS in practice of HTA’ by Wild et al.
|
Cherny, N.I.
|
|
|
27 |
11 |
p. 2136-2137
|
artikel
|
| 23 |
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
|
Ikeda, M.
|
|
|
27 |
11 |
p. 2090-2096
|
artikel
|
| 24 |
Statistical controversies in clinical research: should schedules of tumor size assessments be changed?
|
Filleron, T.
|
|
|
27 |
11 |
p. 1981-1987
|
artikel
|
| 25 |
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression †
|
Obermannová, R.
|
|
|
27 |
11 |
p. 2082-2089
|
artikel
|
| 26 |
Table of Contents
|
|
|
|
27 |
11 |
p. iv-vi
|
artikel
|
| 27 |
The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?
|
Papatla, K.
|
|
|
27 |
11 |
p. 1988-1994
|
artikel
|
| 28 |
The role of opioids in cancer progression: emerging experimental and clinical implications
|
Sjøgren, P.
|
|
|
27 |
11 |
p. 1978-1980
|
artikel
|
| 29 |
Toward the molecular dissection of peritoneal pseudomyxoma
|
Pietrantonio, F.
|
|
|
27 |
11 |
p. 2097-2103
|
artikel
|
| 30 |
Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer
|
Janku, F.
|
|
|
27 |
11 |
p. 2032-2038
|
artikel
|
| 31 |
Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients
|
Cho, Y.
|
|
|
27 |
11 |
p. 2067-2074
|
artikel
|
| 32 |
Utilisation of the ESMO-MCBS in practice of HTA
|
Wild, C.
|
|
|
27 |
11 |
p. 2134-2136
|
artikel
|
Tijdschrift beschrijving